Literature DB >> 28138201

Asenapine for the Control of Physical Aggression: A Prospective Naturalist Pilot Study.

Jin Shi Amon1, Sarah B Johnson1, Rif S El-Mallakh1.   

Abstract

It has been previously purported that higher relative affinity to the dopamine D4 receptor compared to D2 (i.e., D4/D2 affinity ratio > 1) may underlie unique antiaggression potency. Asenapine is a newer antipsychotic that also has D4/D2 affinity ratio > 1. It has demonstrated efficacy in reducing acute agitation in a placebo-controlled study. We performed a prospective naturalistic, pilot, proof of concept study on an inpatient psychiatric unit. Among patients with aggression at time of admission (≥ 12 on Refined Aggression Questionnaire [RAQ], or ≥ 2 on Modified Overt Aggression Scale [MOAS]), asenapine treatment was associated with a significant reduction in total aggression as measured by the MOAS (-14.7 ± 11.59 vs. -5.4 ± 10.12, P = 0.045), and particularly physical aggression (-8.0 ± 5.06 vs. -0.78 ± 2.40, P < 0.0001) compared to treatment that did not include asenapine. These data suggest that asenapine may be useful in the targeted treatment of aggression, and provide some support for the D4/D2 affinity ratio hypothesis.

Entities:  

Keywords:  aggression; asenapine; dopamine receptors; physical aggression; treatment; violence

Mesh:

Substances:

Year:  2017        PMID: 28138201      PMCID: PMC5274528     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  12 in total

1.  Short-term risk prediction: the Brøset Violence Checklist.

Authors:  Roger Almvik; Phil Woods
Journal:  J Psychiatr Ment Health Nurs       Date:  2003-04       Impact factor: 2.952

2.  Voluntary vs. involuntary hospital admission in acute mania of bipolar disorder: results from the Swiss sample of the EMBLEM study.

Authors:  Daniel Schuepbach; Iris Goetz; Heinz Boeker; Daniel Hell
Journal:  J Affect Disord       Date:  2005-12-01       Impact factor: 4.839

3.  Reliability and validity of the Overt Agitation Severity Scale in adult psychiatric inpatients.

Authors:  H J Kopecky; C R Kopecky; S C Yudofsky
Journal:  Psychiatr Q       Date:  1998

4.  A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation.

Authors:  M Pratts; L Citrome; W Grant; L Leso; L A Opler
Journal:  Acta Psychiatr Scand       Date:  2014-03-10       Impact factor: 6.392

5.  Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.

Authors:  L Citrome; J Volavka; P Czobor; B Sheitman; J P Lindenmayer; J McEvoy; T B Cooper; M Chakos; J A Lieberman
Journal:  Psychiatr Serv       Date:  2001-11       Impact factor: 3.084

Review 6.  Aggression in psychiatry wards: a systematic review.

Authors:  Cesare Maria Cornaggia; Massimiliano Beghi; Fabrizio Pavone; Francesco Barale
Journal:  Psychiatry Res       Date:  2011-01-13       Impact factor: 3.222

Review 7.  The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology.

Authors:  Stefano Comai; Michael Tau; Gabriella Gobbi
Journal:  J Clin Psychopharmacol       Date:  2012-02       Impact factor: 3.153

Review 8.  A systematic review of the evidence of clozapine's anti-aggressive effects.

Authors:  Catherine Frogley; David Taylor; Geoff Dickens; Marco Picchioni
Journal:  Int J Neuropsychopharmacol       Date:  2012-02-20       Impact factor: 5.176

9.  Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.

Authors:  S M Essock; L K Frisman; N H Covell; W A Hargreaves
Journal:  Arch Gen Psychiatry       Date:  2000-10

10.  Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.

Authors:  M Shahid; G B Walker; S H Zorn; E H F Wong
Journal:  J Psychopharmacol       Date:  2008-02-28       Impact factor: 4.153

View more
  6 in total

1.  Asenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study.

Authors:  Andrea Aguglia; Ludovico Mineo; Alessandro Rodolico; Maria S Signorelli; Eugenio Aguglia
Journal:  Int Clin Psychopharmacol       Date:  2018-05       Impact factor: 1.659

2.  Cocaine-Induced Psychosis and Asenapine as Treatment: A Case Study.

Authors:  Raul Felipe Palma-Álvarez; Elena Ros-Cucurull; Josep Antoni Ramos-Quiroga; Carlos Roncero; Lara Grau-López
Journal:  Psychopharmacol Bull       Date:  2019-02-15

3.  Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.

Authors:  Paola Bozzatello; Paola Rocca; Maria Uscinska; Silvio Bellino
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

Review 4.  Transdermal Asenapine in Schizophrenia: A Systematic Review.

Authors:  Brennan Carrithers; Rif S El-Mallakh
Journal:  Patient Prefer Adherence       Date:  2020-08-25       Impact factor: 2.711

5.  Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder.

Authors:  Leslie Citrome; Ronald Landbloom; Cheng-Tao Chang; Willie Earley
Journal:  Neuropsychiatr Dis Treat       Date:  2017-12-11       Impact factor: 2.570

6.  Epidemiology of schizophrenia and risk factors of schizophrenia-associated aggression from 2011 to 2015.

Authors:  Yeqing Wu; Ruiying Kang; Yuxiang Yan; Keming Gao; Zhiwu Li; Jun Jiang; Xueyang Chi; Lili Xia
Journal:  J Int Med Res       Date:  2018-08-08       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.